OZEM
Exchange-traded product on NASDAQ (US)
- Type
- Exchange-traded product
- Share class
- —
- Status
- listed
- ISIN
- —
- Currency
- —
- Represents the company
- No
Holdings as of Nov 17, 2026
The full portfolio the fund publishes every business day on its website (roundhillinvestments.com). Every line is listed: holdings we could identify link to their page, the rest (cash, options, swaps, private shares, securities we do not carry) are shown as the fund prints them. Short positions are negative. Change is the share count against Nov 16, 2026.
24 lines, 20 linked, weights sum to 99.98% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | LLY 532457108 | Equity | 8,083 | 0 | 20.49% | $ 11.442M |
| Novo Nordisk A/S | NVO 670100205 | Equity | 149,897 | 0 | 10.92% | $ 6.101M |
| Chugai Pharmaceutical Co Ltd | 4519 JP 6196408 | Equity | 87,300 | 0 | 7.20% | $ 4.023M |
| Hanmi Pharm Co Ltd | 128940 KS B613DJ9 | Equity | 11,503 | 0 | 6.90% | $ 3.855M |
| Pfizer Inc | PFE 717081103 | Equity | 113,197 | 0 | 5.77% | $ 3.223M |
| Kailera Therapeutics Inc | KLRA 482931102 | Equity | 211,629 | 0 | 4.62% | $ 2.582M |
| CSPC Pharmaceutical Group Ltd | 1093 HK 6191997 | Equity | 2,560,000 | 0 | 4.61% | $ 2.574M |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 1276 HK BMV9P26 | Equity | 380,200 | 0 | 4.14% | $ 2.309M |
| Hansoh Pharmaceutical Group Co Ltd | 3692 HK BJYKB72 | Equity | 494,000 | 0 | 3.77% | $ 2.104M |
| Viking Therapeutics Inc | VKTX 92686J106 | Equity | 77,574 | 0 | 3.73% | $ 2.085M |
| AstraZeneca PLC | AZN G0593M107 | Equity | 10,026 | 0 | 3.27% | $ 1.827M |
| Ascletis Pharma Inc | 1672 HK BFLTDL2 | Equity | 3,227,000 | 0 | 3.21% | $ 1.795M |
| Zealand Pharma A/S | ZEAL DC B0SDJB4 | Equity | 50,254 | 0 | 3.04% | $ 1.699M |
| Amgen Inc | AMGN 031162100 | Equity | 3,689 | 0 | 3.02% | $ 1.689M |
|
Roche Holding AG
|
ROP SW BTMJD19 | Equity | 3,213 | 0 | 2.79% | $ 1.555M |
| Structure Therapeutics Inc | GPCR 86366E106 | Equity | 85,120 | 0 | 2.77% | $ 1.547M |
| Gubra A/S | GUBRA DC BMZQSP7 | Equity | 27,580 | 0 | 2.10% | $ 1.173M |
| United Laboratories International Holdings Ltd/The | 3933 HK B1P70H9 | Equity | 1,222,000 | 0 | 2.05% | $ 1.143M |
| Innovent Biologics Inc | 1801 HK BGR6KX5 | Equity | 95,000 | 0 | 1.86% | $ 1.039M |
| MBX Biosciences Inc | MBX 55287L101 | Equity | 18,003 | 0 | 1.71% | $ 955.959K |
| Gilead Sciences Inc | GILD 375558103 | Equity | 4,756 | 0 | 1.45% | $ 809.757K |
|
First American Government Obligations Fund 12/01/2031
|
FGXXX 31846V336 | Money market | 398,085.19 | −2,283,550.95 | 0.71% | $ 398.085K |
|
SWISS FRANC
|
CHF CASHCHF | Equity short | -215,321.29 | −398,430.19 | -0.46% | $ -256.625K |
|
Cash & Other
|
CASH&OTHER CASH&OTHER | Cash | 173,610.55 | +1,156,573.14 | 0.31% | $ 173.611K |